The center will offer training to super-specialist doctors and healthcare professionals in various fields
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Relmada expects to initiate its Phase 3 program in the first half of 2026
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
